Latest

Learn how lung cancer MRD ctDNA testing detects molecular residual disease, what positive and negative results mean, how it can precede recurrence on scans, and why treatment decisions still require clinical context.

Minimal Residual Disease ctDNA Test for Lung Cancer: Recurrence Monitoring, MRD, and Tumor DNA

Learn what MSI testing means in lung cancer, how MSI-H, MSS, dMMR, and pMMR results differ, how NGS, PCR, and IHC are used, and why this rare biomarker can matter for immunotherapy and hereditary evaluation.

MSI Test for Lung Cancer: Microsatellite Instability, Mismatch Repair, and Result Meaning

Learn how Napsin A IHC supports lung adenocarcinoma diagnosis, what positive granular cytoplasmic staining means, why negative results do not exclude lung cancer, and when other tumor origins must be considered.

Napsin A IHC Test for Lung Cancer: Adenocarcinoma Marker, Tumor Origin, and Positive...

Non-Small Cell Lung Cancer Biomarker Test: Driver Mutations, PD-L1, and Molecular Profile

Learn what an NSE blood test means in small cell lung cancer, why levels can be high, how hemolysis causes false elevations, and how serial NSE trends may support treatment and recurrence monitoring.

NSE Test for Lung Cancer: Small Cell Lung Cancer Marker, High Levels, and...

Understand NTRK fusion testing in lung cancer, including tumor-agnostic meaning, RNA NGS, pan-TRK IHC, positive results, negative-result limits, and next steps.

NTRK Fusion Test for Lung Cancer: Gene Fusion, Tumor-Agnostic Marker, and Molecular Meaning

Diagnostics

Home Diagnostics Page 6

Understand Guardant Reveal Test Colorectal Cancer ctDNA MRD and Recurrence Monitoring: what the test measures, how results are interpreted, treatment implications, limitations, and practical next steps.

Guardant Reveal Test: Colorectal Cancer ctDNA MRD and Recurrence Monitoring

Understand HER2 Test for Colon Cancer HER2 Expression, Amplification, and Tumor Marker Meaning: what the test measures, how results are interpreted, treatment implications, limitations, and practical next steps.

HER2 Test for Colon Cancer: HER2 Expression, Amplification, and Tumor Marker...

Understand HER2 Test for Gastric Cancer HER2 Expression, IHC/FISH Status, and Amplification: what the test measures, how results are interpreted, treatment implications, limitations, and practical next steps.

HER2 Test for Gastric Cancer: HER2 Expression, IHC/FISH Status, and Amplification

Understand IDH1 and IDH2 Test for Cholangiocarcinoma Mutation Status and Molecular Meaning: what the test measures, how results are interpreted, treatment implications, limitations, and practical next steps.

IDH1 and IDH2 Test for Cholangiocarcinoma: Mutation Status and Molecular Meaning

Understand KRAS Test for Colon Cancer Mutation Status, Anti-EGFR Resistance Marker, and Meaning: what the test measures, how results are interpreted, treatment implications, limitations, and practical next steps.

KRAS Test for Colon Cancer: Mutation Status, Anti-EGFR Resistance Marker, and...

Understand KRAS Test for Pancreatic Cancer Tumor Mutation, Mutation Status, and Diagnostic Context: what the test measures, how results are interpreted, treatment implications, limitations, and practical next steps.

KRAS Test for Pancreatic Cancer: Tumor Mutation, Mutation Status, and Diagnostic...

Understand Liver Cancer Biomarker Panel AFP, DCP, PIVKA-II, AFP-L3, and HCC Risk: what the test measures, how results are interpreted, treatment implications, limitations, and practical next steps.

Liver Cancer Biomarker Panel: AFP, DCP, PIVKA-II, AFP-L3, and HCC Risk

Understand MLH1 Promoter Methylation Test Colon Cancer, Lynch Syndrome Workup, and Sporadic MSI: what the test measures, how results are interpreted, treatment implications, limitations, and practical next steps.

MLH1 Promoter Methylation Test: Colon Cancer, Lynch Syndrome Workup, and Sporadic...

Understand MMR IHC Test for Colon Cancer MLH1, MSH2, MSH6, PMS2, and Lynch Screening: what the test measures, how results are interpreted, treatment implications, limitations, and practical next steps.

MMR IHC Test for Colon Cancer: MLH1, MSH2, MSH6, PMS2, and...

Learn what MSI-H, dMMR, MSS, and pMMR mean in colon cancer, how MSI testing guides immunotherapy, and when an abnormal result can lead to Lynch syndrome testing.

MSI Test for Colon Cancer: Microsatellite Instability, Lynch Syndrome, and Mismatch...

Understand MSI testing in gastric cancer, including MSI-H, dMMR, MSS, molecular subtype, immunotherapy relevance, and when a result may prompt Lynch syndrome evaluation.

MSI Test for Gastric Cancer: Microsatellite Instability, Mismatch Repair, and Molecular...

Learn what an NRAS mutation means in colon cancer, why NRAS predicts resistance to cetuximab and panitumumab, and how wild-type results fit into extended RAS testing.

NRAS Test for Colon Cancer: Mutation Status, Anti-EGFR Resistance Marker, and...

Learn how NTRK fusion testing works in colon cancer, what a positive fusion means, why NTRK is a tumor-agnostic marker, and how TRK inhibitors may be used in advanced disease.

NTRK Fusion Test for Colon Cancer: Gene Fusion, Tumor-Agnostic Marker, and...

Learn how the Oncotype DX Colon Recurrence Score works, what a 0–100 genomic score means, and how it can refine recurrence-risk discussions after colon cancer surgery.

Oncotype DX Colon Recurrence Score Test: Colon Cancer Recurrence Risk and...

Learn what a PALB2 result means in pancreatic cancer, how germline and tumor variants differ, why platinum sensitivity matters, and when hereditary family testing is needed.

PALB2 Test for Pancreatic Cancer: DNA Repair Marker, Hereditary Risk, and...

Understand pancreatic cancer biomarkers including CA 19-9, CEA, KRAS, BRCA, PALB2, MSI, and gene fusions, with practical guidance on monitoring, hereditary risk, and targeted therapy.

Pancreatic Cancer Biomarker Panel: CA 19-9, CEA, KRAS, BRCA, PALB2, and...

Learn how PD-L1 CPS is calculated in gastric cancer, what CPS ≥1 and CPS ≥5 mean, and how expression level guides immunotherapy alongside HER2 and MSI testing.

PD-L1 Test for Gastric Cancer: CPS Score, Expression Level, and Immunotherapy...

Learn what a high PIVKA-II or DCP result means, which noncancer conditions can raise it, and how the marker is used with AFP and imaging for HCC risk and monitoring.

PIVKA-II Test for Liver Cancer: High Levels, HCC Risk, and Monitoring

Learn how Signatera uses tumor-informed ctDNA to detect molecular residual disease after colon cancer treatment, what positive and negative results mean, and how MRD monitoring may guide care.

Signatera Test for Colon Cancer: ctDNA Recurrence Monitoring and MRD Detection

Learn what SMAD4 loss means in pancreatic cancer, how IHC and sequencing detect it, what studies show about prognosis, and why SMAD4 is not yet a stand-alone treatment target.

SMAD4 Test for Pancreatic Cancer: Tumor Suppressor Marker, Loss, and Prognosis

1...567...92 Page 6 of 92